Cdc50C Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus structure by inhibiting ADP-ribosylation factor (ARF), which is crucial for vesicle formation in the secretory pathway. As Cdc50C is associated with trafficking and transport processes, the disruption of Golgi apparatus function by Brefeldin A likely leads to the diminished functional activity of Cdc50C. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore is a GTPase inhibitor that impairs dynamin-mediated endocytosis. Since Cdc50C may be involved in vesicular transport, inhibiting endocytosis can indirectly decrease the functional activity of Cdc50C by preventing its proper localization to cellular membranes. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML 141 is a selective inhibitor of Cdc42, a small GTPase. By inhibiting Cdc42, which is involved in actin cytoskeleton organization, ML 141 can indirectly lead to diminished functional activity of Cdc50C if Cdc50C's function is linked to cytoskeletal dynamics or cell morphology. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that disrupts intracellular ion gradients and affects vesicle acidification. This ion disruption can indirectly diminish the activity of Cdc50C by altering the ion-dependent processes it requires for proper function. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule polymerization. If Cdc50C is involved in processes that require intact microtubules, such as vesicle transport or cell division, nocodazole's action would indirectly lead to decreased functionality of Cdc50C by impairing those processes. | ||||||
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $321.00 $1040.00 | 5 | |
CK 666 is an Arp2/3 complex inhibitor, which prevents actin nucleation and branching. If Cdc50C function is associated with actin-based structures, CK-666 would indirectly decrease its activity by destabilizing those structures. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö 6976 is a protein kinase C (PKC) inhibitor. PKC is involved in various signaling pathways, and if Cdc50C is regulated by PKC-mediated phosphorylation, Gö6976 could indirectly decrease the functional activity of Cdc50C. | ||||||
Latrunculin B | 76343-94-7 | sc-203318 | 1 mg | $240.00 | 29 | |
Latrunculin B binds to actin monomers and prevents their polymerization. If Cdc50C is involved in processes that depend on actin filament formation, the presence of Latrunculin B would indirectly lead to a decrease in Cdc50C activity. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
ZCL278 is an inhibitor of Cdc42-mediated signaling. This compound would indirectly diminish Cdc50C activity if it is involved in Cdc42-dependent pathways, especially those linked to vesicle formation and trafficking. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide stabilizes actin filaments and prevents their disassembly. As Cdc50C may function in concert with dynamic actin structures, stabilization by Jasplakinolide could paradoxically decrease Cdc50C activity by impeding actin turnover required for its function. | ||||||